Company profile for Arcellx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Arcellx is a privately held development-stage company founded in 2015 & located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, & responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across ...
Arcellx is a privately held development-stage company founded in 2015 & located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, & responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. Our vision is to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, & reprogrammed throughout the course of disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
25 West Watkins Mill Road, Suite A Gaithersburg, MD 20878
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251118380200/en/Arcellx-to-Host-Investor-Relations-Event-During-the-67th-ASH-Annual-Meeting-and-Exposition

BUSINESSWIRE
18 Nov 2025

https://www.fiercepharma.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t

FIERCE PHARMA
12 Nov 2025

https://www.businesswire.com/news/home/20251105692455/en/Arcellx-Provides-Third-Quarter-2025-Financial-Results

BUSINESS WIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251103032157/en/Arcellx-to-Present-New-Data-for-Its-iMMagine-1-Study-and-Continues-Scientific-Momentum-with-Multiple-Presentations-at-the-67th-ASH-Annual-Meeting-and-Exposition

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20251102053147/en/Gilead-and-Kite-Showcase-Continued-Progress-in-Transforming-Blood-Cancer-Care-With-New-Cell-Therapy-Data-at-ASH-2025

BUSINESSWIRE
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-09-03/arcellx-to-participate-at-the-2025-morgan-stanley-global-healthcare-conference

PHARMAWEB
03 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty